Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 13/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.63 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | PTPRC | P08575 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2568289 | 0.83 | PTGS2 (0.68) | PTGS1PTGS2 | |
| Hydrochloric Acid SCHEMBL5794623 | 0.81 | PTGS2 (0.66) | PTGS1PTGS2 | |
| SCHEMBL8657273 | 0.80 | PTGS2 (0.69) | PTGS1PTGS2 | |
| SCHEMBL3248281 | 0.78 | PTGS1 (1.00) | PTGS1PTGS2MAPK14 | |
| SCHEMBL3246289 | 0.78 | PTGS1 (1.00) | PTGS1PTGS2MAPK14 | |
| SCHEMBL8871414 | 0.77 | PTGS2 (0.65) | PTGS1PTGS2 | |
| SCHEMBL8661267 | 0.75 | PTGS2 (0.64) | PTGS1PTGS2 | |
| SCHEMBL8350056 | 0.74 | CA1 (0.54) | PTGS1PTGS2 | |
| SCHEMBL22261486 | 0.72 | PTGS1 (0.54) | PTGS1PTGS2MAPK14 | |
| SCHEMBL10843937 | 0.72 | MAPK14 (0.79) | PTGS1PTGS2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390026-B1 | TREATMENT OF HPV CAUSED DISEASES | CORNELL RES FOUNDATION INC (US) | 2010-05-05 | — | — | EP | claimed |
| EP-1146789-B1 | TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF HER-2/NEU | CORNELL RES FOUNDATION INC (US) | 2009-03-18 | — | — | EP | claimed |
| EP-1146789-B1 | TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF HER-2/NEU | CORNELL RES FOUNDATION INC (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-1039914-A4 | CYCLOOXYGENASE-2 INHIBITION | CORNELL RES FOUNDATION INC (US) | 2007-06-27 | — | — | EP | disclosed |
| US-7041694-B1 | Cyclooxygenase-2 inhibition | CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1109553-A4 | TREATING INFLAMMATORY DISEASES OF THE HEAD AND NECK WITH CYCLOOXYGENASE-2 INHIBITORS | CORNELL RES FOUNDATION INC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-6486194-B2 | ALZHEIMER'S DISEASE | MERCK FROSST CANADA, INC. (CA) | 2002-11-26 | — | — | US | disclosed |
| US-6486203-B1 | Treating inflammatory diseases of the head and neck with cyclooxygenase-2 inhibitors | CORNELL RESEARCH FOUNDATION, INC. | 2002-11-26 | — | — | US | disclosed |
| US-6403630-B1 | ADMINISTERING A CYCLOOXYGENASE-2 (COX-2) INHIBITOR ALONE OR IN COMBINATION WITH HERCEPTIN? ANTIBODY; USED TO TREAT BREAST CANCER | CORNELL RESEARCH FOUNDATION, INC. | 2002-06-11 | — | — | US | disclosed |
| US-20010016595-A1 | Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases | MERCK FROSST CANADA INC./MERCK FROSST CANADA & CO. | 2001-08-23 | — | — | US | disclosed |
| EP-1109553-A1 | TREATING INFLAMMATORY DISEASES OF THE HEAD AND NECK WITH CYCLOOXYGENASE-2 INHIBITORS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2001-06-27 | — | — | EP | disclosed |
| EP-0822190-A1 | Phenyl heterocycles as cyclooxygenase-2 inhibitors | MERCK FROSST CANADA INC. (CA) | 1998-02-04 | — | — | EP | disclosed |
| US-5710140-A | ANTIINFLAMMATORY AGENT; ANALGESICS; ANTIPYRETIC AGENT | MERCK FROSST CANADA, INC. (CA) | 1998-01-20 | — | — | US | disclosed |
| EP-0754687-A1 | Phenyl heterocycles as cyclooxygenase-2 inhibitors | MERCK FROSST CANADA INC. (CA) | 1997-01-22 | — | — | EP | disclosed |
| EP-0739340-A1 | PHENYL HETEROCYCLES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1996-10-30 | — | — | EP | disclosed |
| US-5550142-A | CYCLOOXYGENASE INHIBITORS; ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETIC AGENTS | MERCK FROSST CANADA INC. (CA) | 1996-08-27 | — | — | US | disclosed |
| US-5536752-A | TREATMENT OF CYCLOOXYGENASE-2 MEDIATED DISEASES; ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA INC. (CA) | 1996-07-16 | — | — | US | disclosed |
| EP-0705254-A1 | PHENYL HETEROCYCLES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1996-04-10 | — | — | EP | disclosed |
| US-5474995-A | Nonsteroidal, antiinflammatory agents | MERCK FROSST CANADA, INC. (CA) | 1995-12-12 | — | — | US | disclosed |
| WO-1995000501-A2 | PHENYL HETEROCYCLES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016595-A1 | Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases | PTGS1, PTGES2, PTGS2 | PTGS1 1/4885PTGS2 3/4885MAPK14 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.